

2024 ASCLS-ND "Spring Symposium" From Lab to Life: Enhancing Patient Care

American Society for Clinical Laboratory Science - North Dakota

Gateway to Science, Bismarck, ND

Time / codes	Program Outline
8:00-8:50	Steve Mahlen, PhD, D (ABMM)
# 165-001-24	Director, Microbiology, Sanford Bismarck
	Title: Emerging Resistant Pathogens (M)
Intermediate	Summary: The emergence of Candida auris and carbapenem-resistant organisms (CRO) are a serious medical and public health threat. Identification of
	C. auris and detection of resistance mechanisms is complex but extremely important. This session will focus on C. auris and CRO identification with
PACE:	some interesting case studies.
	Objectives:
	Discuss the public health threat that C. auris poses and the ways that this organism can be identified.
	Describe the phenotypic and genotypic methods used to detect carbapenem resistance in Gram-negative bacteria.
9:00-9:50	Shelly Heilman, MLS (ASCP),
#165-002-24	Health Facilities Surveyor, North Dakota Dept of Health and Human Services, Health Facilities Unit.
Basic	Title: CLIA: Lab Quality Enhances Patient Care (QA)
	Summary: Provide education and information regarding issues affecting North Dakota CLIA laboratories.
PACE:	Objectives:
	Identify the most common CLIA deficiencies in North Dakota.
	Evaluate CLIA hot topics.
10:00-10:50	Stacey Alexander MLS(ASCP)
# 165-003-24	Biothreat Laboratory Director
	Title: Missed or Misidentified Microorganisms: Francisella and Brucella Species (M)
Basic –	Summary: This presentation delves into the challenges surrounding the identification of Francisella and Brucella species, emphasizing the clinical
Intermediate	significance of accurate identification. It explores the complexities in identifying these microorganisms. Current diagnostic methods and their limitations
	are examined, highlighting potential consequences of misidentification. Ultimately, the objective is to raise awareness, evaluate challenges, and promote
	measurable improvements in the accuracy and efficiency of microorganism identification to positively impact patient outcomes and public health.
PACE:	Objectives:
	> Describe the clinical significance of Francisella and Brucella species and the potential impact of misidentification on patient outcomes and public
	health.
	Identify the limitations of current diagnostic methods for bacterial culture and identification.
	List strategies to enhance detection and improve identification of Francisella and Brucella species.
	Karen Wyatt MBA, MLS(ASCP)CM
11:00-11:50	Cellavision, Market Support Manager
# 165-004-24	Topic: Digital Cell Imaging with Esoteric Case Studies (H)
	Summary : This session will demonstrate how automated digital imaging systems can improve turnaround time and improve competency and
Intermediate	standardization using artificial neural networks that have been trained with deep learning. It will be filled with case studies to show how such technology
	can automate the most subjective area of the laboratory, the manual differential bench.
PACE:	Objectives :
	Discuss how neural networks standardize subjectivity in neural networks
	Describe how remote review software can improve turnaround time and pathology reviews
	Discuss and share some of the most esoteric case studies available
2:00-12:50	LUNCH/BUSINESS MEETING



2024 ASCLS-ND "Spring Symposium"

From Lab to Life: Enhancing Patient Care

American Society for Clinical Laboratory Science - North Dakota

Gateway to Science, Bismarck, ND

Time / codes	Program Outline
1:00-1:50	Casey Nelson, PharmD, BCOP
# 165-005-24	Clinical Science Liaison
	Title: Utilization of host-immune response to determine bacterial vs viral source of acute infection in pediatric and adult patients (IM)
	Summary: Distinguishing between bacterial and viral infections can be challenging, leading to inappropriate use of antibiotics that may contribute to the
	development of bacterial antibiotic resistance. Humans mount immune responses to bacteria and viruses that are qualitatively and quantitatively different.
Intermediate	These differences can be exploited to distinguish between these types of infection, which is important in choosing the correct therapy for the patient. In
D. CE	this session we will review recent advances in the development and validation of host-response biomarkers for the diagnosis of bacterial and viral
PACE:	infections. We will then present several case studies in which a new test measuring serum CRP, IP-10 and TRAIL successfully identifies the bacterial or
	viral etiology of infection.
	 Objectives: > Recognize the challenges for laboratories and clinicians in distinguishing between bacterial and viral infections.
	 Discuss the potential impact of host biomarker technology on clinical decision making and antimicrobial stewardship.
	 Discuss the potential impact of host biomarker technology on emilear decision making and antimicrobial second signal. Describe the utility and potential limitations of host biomarker analysis in the clinical assessment of patients with possible acute infections
2:00-2:50	Karen Peterson M.S. MLS(ASCP)CM
# 165-006-24	Clinical Education Coordinator
	Title: Acute Kidney Injury (C/U)
	Summary: Acute Renal Failure has been reclassified to Acute Kidney Injury (AKI). Diagnosis of AKI is based on specific criteria which monitor rapid
Intermediate	changes in renal testing results. To troubleshoot results it is important to understand the role of blood pressure in the renal system, kidney function, and
	renal function tests.
PACE:	Objectives:
	Evaluate the role of blood pressure in renal disease.
	 Identify causes of Pre-Renal, Renal, and Post Renal Acute Kidney Injury Associate laboratory result criteria for an Acute Kidney Injury Diagnosis
3:00-4:50	Jorden Laducer-Dix
Basic -	Special Population Coordinator
Intermediate	Title: Understanding Bias Public Health/Health Equity (ME)
Interneturate	Summary: This presentation will provide the knowledge and skills needed to develop new structures, practices, and approaches to improve outcomes
Part1	and quality of life for North Dakotans, including learning information and insights they need to identify inequities in the workplace. Upon completing this
# 165-007-24	presentation, participants will gain knowledge by understanding Health Equity, Bias, Microaggressions, Racism, Stereotypes and Discrimination.
PACE:	Objectives:
	Define health equity and discuss why it matters
	List social determinates of health
D. (2	Describe cultural competency
Part2 # 165-008-24	 Define bias and describe why is matters List key principles of implicit bias
# 165-008-24 PACE:	 List key principles of implicit bias. Define microaggressions and stereotypes
IACL.	 Identify strategies to deal with implicit bias
Discipline codes	Microbiology (M), Quality Assurance (QA), Hematology (H), Immunology (IM), Chemistry (C), Urinalysis (U), Medical Ethics (ME)